What are your top takeaways in Gyn Cancers from ESMO 2024?

There has been limited success with single agent immunotherapy in ovarian cancer. Three ovarian cancer immunotherapy studies presented at ESMO 2024 are worth noting.

ATHENA-COMBO: Rucaparib +/- Nivo as Maintenance in Newly Diagnosed Ovarian Cancer - ATHENA-COMBO Ph3 Trial

ATHENA had two components. The first, ATHENA-MONO (previously reported) evaluated Rucaparib as maintenance in patients with newly diagnosed ovarian cancer. The second, ATHENA-COMBO was presented at ESM...